Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme’s Vytorin shows efficacy in study

Merck Sharpe and Dohme’s Vytorin shows efficacy in study

22nd November 2010

Merck Sharpe and Dohme's new cholesterol-lowering drug Vytorin has shown its lifesaving benefits for chronic kidney disease (CKD) patients in a new trial.

The medicine reduced the incidence of first major vascular events among sufferers of the disease compared to placebo by a statistically significant margin during the Sharp investigational study.

It means that the treatment met its primary efficacy endpoint, showing for the first time that a low-density lipoprotein cholesterol-lowering treatment can help to mitigate the risk of major vascular and atherosclerotic events in this patient group.

Merck Sharpe and Dohme will now be seeking regulatory approval for the treatment in this indication, based on the trial data.

Dr Peter Kim, president of Merck Research Laboratories, said: "We thank Oxford University and the thousands of patients and healthcare professionals who participated in Sharp for their contributions to this study to address this important medical question for patients with CKD."

Last week, the company published data from a trial of anacetrapib, showing how the drug can help to treat coronary heart disease by regulating cholesterol levels.ADNFCR-8000103-ID-800249820-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.